4 results
Search Results
2. Roles of γδ T Cells in the Pathogenesis of Autoimmune Diseases.
- Author
-
Dinglei Su, Minning Shen, Xia Li, and Lingyun Sun
- Subjects
T cells ,AUTOIMMUNE diseases ,TISSUES ,AUTOANTIBODIES ,CARCINOGENESIS ,CYTOKINES ,DISEASES - Abstract
γδ T cells are a minor population of T cells that express the TCR γδ chains, mainly distributed in the mucosal and epithelial tissue and accounting for less than 5% of the total T cells in the peripheral blood. By bridging innate and adaptive immunity, γδ T cells play important roles in the anti-infection, antitumor, and autoimmune responses. Previous research on γδ T cells was primarily concentrated on infectious diseases and tumors, whereas their functions in autoimmune diseases attracted much attention. In this paper, we summarized the various functions of γδ T cells in two prototypical autoimmune connective tissue diseases, that is, SLE and RA, elaborating on their antigen-presenting capacity, secretion of proinflammatory cytokines, immunomodulatory effects, and auxiliary function for B cells, which contribute to overproduction of proinflammatory cytokines and pathogenic autoantibodies, ultimately leading to the onset of these autoimmune diseases. Elucidation of the roles of γδ T cells in autoimmune diseases is not only conducive to in-depth understanding of the pathogenesis of these diseases, but also beneficial in providing theoretical support for the development of γδ T-cell-targeted therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
3. Mesenchymal StemCells as Immunomodulators in a Vascularized Composite Allotransplantation.
- Author
-
Yur-Ren Kuo, Chien-Chang Chen, Shigeru Goto, Pao-Yuan Lin, Fu-ChanWei, and Chao-Long Chen
- Subjects
MESENCHYMAL stem cells ,IMMUNOMODULATORS ,IMMUNOSUPPRESSIVE agents ,AUTOIMMUNE diseases ,T cells - Abstract
Vascularized composite allotransplantations (VCAs) are not routinely performed for tissue reconstruction because of the potentially harmful adverse effects associated with lifelong administration of immunosuppressive agents. Researchers have been eagerly seeking alternative methods that circumvent the long-term use of immunosuppressants. Mesenchymal stem cells (MSCs) show promise as an immunomodulatory therapeutic agent and are currently being tested in preclinical and clinical settings as therapies for autoimmune disorders or transplant rejection. The mechanisms by which MSCs modulate the immune response are still under thorough investigation, but these most likely involve expression of local factors influencing T-cell regulation, modulation of cytokine expression (e.g., IL-10, TGF-β, TNF-α, INF-γ, etc.), and interactions with dendritic or antigen presenting cells. In this paper, we summarize the current understanding of immunomodulation achieved by MSC therapies and introduce a possible outline for future clinical applications in VCA. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
4. Immune-Regulatory Mechanisms in Systemic Autoimmune and Rheumatic Diseases.
- Author
-
Konttinen, Yrjö T. and Takakubo, Yuya
- Subjects
AUTOIMMUNE diseases ,RHEUMATISM ,IMMUNOREGULATION ,IMMUNOLOGICAL tolerance ,DENDRITIC cells ,T cells ,B cells - Abstract
Systemic autoimmune and rheumatic diseases (SAIRDs) are thought to develop due to the failure of autoimmune regulation and tolerance. Current therapies, such as biologics, have improved the clinical results of SAIRDs; however, they are not curative treatments. Recently, new discoveries have been made in immune tolerance and inflammation, such as tolerogenic dendritic cells, regulatory T and B cells, Th 17 cells, inflammatory and tolerogenic cytokines, and intracellular signaling pathways. They lay the foundation for the next generation of the therapies beyond the currently used biologic therapies. New drugs should target the core processes involved in disease mechanisms with the aim to attain complete cure combined with safety and low costs compared to the biologic agents. Re-establishment of autoimmune regulation and tolerance in SAIRDs by the end of the current decade should be the final and realistic target. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.